Soligenix reports positive topline results from Phase 3 cutaneous T-cell lymphoma trial


Soligenix (NASDAQ:SNGX) reported positive topline results for its Phase 3 trial assessing SGX301 for the treatment of cutaneous T-cell lymphoma (CTCL).

The study enrolled 169 patients who were randomized to receive either SGX301, a synthetic hypericin, or placebo for three treatment cycles of eight weeks each. Topline results from the first cycle demonstrated a statistically significant reduction of lesions in patients receiving SGX301.

A preliminary assessment of the second cycle results suggests a significantly more robust response rate. Data from the second cycle are expected in June 2020.

“These results support our long-standing belief that SGX301 has the potential to be a valuable therapy in the treatment of early stage CTCL, which is an orphan disease and area of unmet medical need,” Christopher Schaber, Soligenix’s president and CEO, said in a statement.

“We will now look to move as quickly as possible to complete a full analysis of the data for publication, as well as begin preparations for a robust discussion with the FDA regarding this important dataset,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.